Protalix Chairman Hurvitz resigns to recover from illness, replaced by board member Bronfeld

Protalix chairman resigns for health reasons

SEATTLE — Protalix Biotherapeutics Inc., a pharmaceutical company, said Tuesday its chairman of the board is resigning to recover from an illness.

Carmiel, Israel-based Protalix said Eli Hurvitz is stepping down. Zeev Bronfeld, another board member, will serve as interim chairman effective immediately.

Bronfeld was Protalix’s first investor. He co-founded Biocell Ltd., a biotech holding company, and is a member of the board of several other publicly traded companies.